Clinical trials: Hepatotoxicity
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
Acute Lymphoblastic Leukemia, Pancreatitis
PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL
The purpose of this study is to create a model enabling us to predict pancreatitis, hyperlipidemia and hepatotoxicity during treatment with PEG-Asparaginase in children with Acute Lymphoblastic Leukemia.
- Trial name
- AAP2008 (NCT01393249)
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Infection, Human Immunodeficiency Virus I
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg.
- Trial name
- NCT03327740
- Testing
- DTG based ARV regimen with ABC, DTG based ARV regimen without ABC, RAL or EGV based ARV regimens with ABC
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Hepatitis, Tuberculosis
Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity
The purpose of this study is to evaluate plasma levels of hepatotoxic anti-tuberculous drugs (isoniazid, rifampicin, pyrazinamide plus significant metabolites) among patients on antituberculosis treatment (ATT) and compare the…
- Trial name
- NCT00929786
- Where
- 2 sites in India
- Volunteers
- 72 people
- Sponsor
- All India Institute of Medical Sciences
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia
Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia
Study the role of oxidative stress in methotrexate induced hepatic damage, and the possible protective effect of OMEGA-3 fatty acids against methotrexate hepatotoxicity using clinical and biochemical parameters.
- Trial name
- NCT02373579
- Testing
- Omega-3 Fatty Acids, Methotrexate
- Volunteers
- 70 people
- Sponsor
- Nancy Samir Elbarbary
Drug Induced Hepatotoxicity, Tuberculosis
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage
Purpose of the study is to evaluate the safety and efficacy of different re-introduction regimens in anti-TB drug induced liver damage. There is no consensus how best to treat such patients who developed drug induced liver damage.
- Trial name
- NCT00405301
- Testing
- Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
- Where
- 2 sites in India
- Volunteers
- 175 people
- Sponsor
- All India Institute of Medical Sciences
Acute Lymphoblastic Leukemia, Hepatotoxicity
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the most common cancer seen in pediatric oncology. The necessary chemotherapy for pediatric and adolescent and young adult (AYA) patients with ALL includes steroids, anthracyclines…
- Trial name
- NCT05501899
- Testing
- Levocarnitine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Orange County
Drug-induced Disorder of Liver, Adverse Reaction to Drug
Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity
Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults).
- Trial name
- NCT02353455
- Testing
- Blood sampling
- Where
- 5 sites in Australia, Germany and 3 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Andreas Benesic, MD
Cancer
Hepatotoxicity Related to Protein Kinase Inhibitors
Although protein kinase inhibitors (PKIs) have proved effective in treating many cancers, few patients receiving PKIs may experience rare but life-threatening hepatotoxicity such as hepatic failure.
- Trial name
- NCT05430126
- Testing
- Protein Kinase Inhibitor
- Where
- China
- Volunteers
- 600,000 people
- Sponsor
- Central South University
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma.
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
- Trial name
- NCT05602194
- Testing
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine
- Where
- 228 sites in United States, Canada
- Volunteers
- 440 people
- Sponsor
- Children's Oncology Group